Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
002675.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.05B
Close$
$3.62
73% downside
Current Fair Value
73% downsideOvervalued by 73% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.05 Billion |
|---|---|
| Enterprise Value | $11.74 Billion |
| Dividend Yield | $0.08 (0.60%) |
| Earnings per Share | $0.24 |
| Beta | -0.08 |
| Outstanding Shares | 817,196,206 |
Return
| Return on Equity | 4.56% |
|---|---|
| Return on Assets | 2.17% |
| Return on Invested Capital | 5.71% |
Valuation & Multiples
| P/E Ratio | 54.9 |
|---|---|
| PEG | -970.33 |
| Price to Sales | 4.47 |
| Price to Book Ratio | 2.23 |
| Enterprise Value to Revenue | 4.4 |
| Enterprise Value to EBIT | 27.56 |
| Enterprise Value to Net Income | 58 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.32 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 22, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$682.55 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.09
Average shareholder expectationRevenue Estimate
$677.56 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
2,583 employees
CEO: Zhi Gang Luo Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others s...